BioVaxys announces completed synthesis of its Pan-Sarbecovirus Vaccine candidate and launch of in vivo animal study
The next step is measuring neutralizing antibody development to sarbecoviruses following immunization of study animals with BVX-1021, followed by administration of a SARS-CoV-2 vaccine---in this case with BVX-0320, the Company's Covid-19 vaccine candidate.
- The next step is measuring neutralizing antibody development to sarbecoviruses following immunization of study animals with BVX-1021, followed by administration of a SARS-CoV-2 vaccine---in this case with BVX-0320, the Company's Covid-19 vaccine candidate.
- BVX-1021 is the subject of an ongoing research collaboration betweenOSU and BioVaxys that is evaluating the Company's novel approach for a "universal vaccine" that can treat a broad range of sarbecoviruses.
- The collaboration, which began earlier this year, is evaluating the combination of BioVaxys' BVX-0320 and BVX-1021 in a guinea pig model.
- BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB:BVAXF).